<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6380">
  <stage>Registered</stage>
  <submitdate>14/10/2016</submitdate>
  <approvaldate>14/10/2016</approvaldate>
  <nctid>NCT02935634</nctid>
  <trial_identification>
    <studytitle>A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer</studytitle>
    <scientifictitle>A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)</scientifictitle>
    <utrn />
    <trialacronym>FRACTION-GC</trialacronym>
    <secondaryid>2016-002807-24</secondaryid>
    <secondaryid>CA018-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Gastric Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Stomach</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Nivolumab
Other interventions - Ipilimumab
Other interventions - Relatlimab

Active Comparator: Nivolumab and Ipilimumab Combination - Nivolumab and Ipilimumab Combination

Experimental: Nivolumab and Relatlimab Combination - Nivolumab and Relatlimab Combination


Other interventions: Nivolumab


Other interventions: Ipilimumab


Other interventions: Relatlimab


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Objective Response Rate (ORR)</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Duration of Response (DOR)</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Progression-free Survival Rate (PFSR)</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Adverse Events (AEs)</outcome>
      <timepoint>Up to 38 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Serious Adverse Events (SAEs)</outcome>
      <timepoint>Up to 38 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AEs leading to discontinuation</outcome>
      <timepoint>Up to 38 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AEs leading to death</outcome>
      <timepoint>Up to 38 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        

          -  Advanced Gastric Cancer

          -  Must have full activity or, if limited, must be able to walk and carry out light
             activities such as light house work or office work

          -  Must have at least 1 lesion with measurable disease</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>110</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients/subjects with HER2 positive tumor that have not been treated with trastuzumab
             prior to enrollment

          -  Must not have suspected or known central nervous system metastases unless adequately
             treated

          -  Patients/subjects with autoimmune disease

          -  Patients/subjects who need daily oxygen therapy

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>23/11/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>18/11/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Local Institution - Westmead</hospital>
    <hospital>Local Institution - Heidelberg</hospital>
    <hospital>Local Institution - Randwick</hospital>
    <postcode>2145 - Westmead</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>2031 - Randwick</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv, Israel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona-barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Chur</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether Nivolumab in combination with other
      therapies is more effective than Nivolumab in combination with Ipilimumab in treating
      patients/subjects with advanced gastric cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02935634</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</name>
      <address />
      <phone>please email:</phone>
      <fax />
      <email>Clinical.Trials@bms.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>